BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 20028212)

  • 1. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
    Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
    Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learnt from MDM2 fluorescence in-situ hybridisation analysis of 439 mature lipomatous lesions with an emphasis on atypical lipomatous tumour/well-differentiated liposarcoma lacking cytological atypia.
    Vargas AC; Joy C; Cheah AL; Jones M; Bonar F; Brookwell R; Garrone B; Talbot J; Harraway J; Gill AJ; Maclean FM
    Histopathology; 2022 Jan; 80(2):369-380. PubMed ID: 34523152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
    Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
    Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective.
    Clay MR; Martinez AP; Weiss SW; Edgar MA
    Am J Surg Pathol; 2016 Dec; 40(12):1647-1652. PubMed ID: 27508976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Li-Fraumeni syndrome].
    Frebourg T
    Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
    Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
    Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
    Wu CC; Krahe R; Lozano G; Zhang B; Wilson CD; Jo EJ; Amos CI; Shete S; Strong LC
    Hum Genet; 2011 Jun; 129(6):663-73. PubMed ID: 21305319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
    Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
    Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling of a unique liposarcoma arising in a patient with Li-Fraumeni syndrome and the novel detection of c-myc amplification: a case report.
    Watanabe H; Fujishima F; Motoi T; Aoyama Y; Niihori T; Takahashi M; Umegaki S; Oishi H; Tada H; Ichinohasama R; Sasano H
    Diagn Pathol; 2022 Dec; 17(1):93. PubMed ID: 36514176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
    Boltze C; Schneider-Stock R; Jäger V; Roessner A
    Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
    Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
    Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposarcoma in children and young adults: a clinicopathologic and molecular study of 23 cases in one of the largest institutions of China.
    Peng R; Li N; Lan T; Chen H; Du T; He X; Chen M; Xie Y; Zhang Z; Zhao W; Zhang H
    Virchows Arch; 2021 Sep; 479(3):537-549. PubMed ID: 33738541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
    Evans SC; Lozano G
    Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
    Jing W; Lan T; Chen H; Zhang Z; Chen M; Peng R; He X; Zhang H
    Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-differentiated liposarcoma associated with benign lipoma.
    Hatano H; Morita T; Ogose A; Hotta T; Kobayashi H; Honma K
    Anticancer Res; 2004; 24(2C):1039-44. PubMed ID: 15154619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.